Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego

RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi

Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech

Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina

San Diego upstart acquires RNA tech from cash-strapped Marina Biotech

San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More

Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech

Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations

GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug

RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes

Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014

Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014

San Diego's Arcturus Raises $5M for 'Best-in-Class' RNAi Technology

Arcturus Raises $5M in Series A Funding

Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery

Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014

Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program

Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program

Arcturus Therapeutics to Present at the Keystone Symposia Conference on RNA Silencing

Arcturus Therapeutics to Present RNAi Data for Orphan Diseases Utilizing the LUNARTM Technology Platform at BIOCOM's Global Life Science Partnering Conference

Arcturus Releases Data Showing Potential of Delivery Technology for CRISPR Drugs

Arcturus Therapeutics to Present at the BIO-Europe Spring Partnering Conference

Arcturus Therapeutics to Present at the BioCentury Future Leaders in the Biotech Industry Conference

Arcturus Therapeutics to Present at the 13th Annual Needham Healthcare Conference

Arcturus Therapeutics Appoints Robert Baltera and Stuart Collinson, Ph.D. to its Board of Directors

Arcturus Therapeutics Announces Allele-Specific Silencing Technology at IBC’s 16th Annual TIDES Conference

Why San Diego is a Hub for RNA R&D and Drug Development

Arcturus Therapeutics to Present Gene Knockdown Data in Non-Human Primates, Showing up to 94% Reduction in Gene Expression with a Single Low Dose

Arcturus Touts Dosing, Specificity of ATTR Drugs as They Move Toward Clinic

Top 30 Life Science Startups To Watch In The U.S.

Arcturus Therapeutics expands in La Jolla

Arcturus Therapeutics Expands Operations in San Diego, CA

Arcturus Therapeutics Presents Preclinical Messenger RNA Data in Non-Human Primates at the 2nd International mRNA Health Conference

Arcturus Demonstrates mRNA Delivery to Primates, Sees Possible Rx by 2016

Arcturus Presents mRNA Delivery Data Applicable to CF Treatment

Arcturus shoots for 'LUNAR' landing in treating rare diseases

Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference

Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. to the Scientific Advisory Board

Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase

Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications

2015 Oligonucleotide Therapeutics Society

Ultragenyx gives Arcturus rocket shot in potential $1.57B deal

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board

International mRNA Health Conference

Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016

Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology

Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco

November 1-2, 2016

Arcturus Therapeutics to Report Identification of LUNAR-HBV, a Potent Combination of Three UNA Oligomers Targeting All Hepatitis B Virus Genotypes at the AASLD Liver Meeting® 2016

Big Pharma Goes Small With Moves Into Incubator Space

nature Biotechnology and nature Reviews Drug Discovery

Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)

East West CEO Conference-Panel Discussion on Mid-Cap Biotech: Challenges and Opportunities

Fierce Innovation Awards 2016 Life Science Edition

From Incubation to Investment: The Trajectory of Arcturus Therapeutics

Arcturus Therapeutics to Present at the 19th Annual Bio CEO and Investor Conference in NY

Collaboration between Salk institute (Verma lab) and Arcturus Therapeutics Inc. to treat hemophilia B in mice

PNAS Publication on Arcturus and Salk--Systemic delivery of factor IX messenger RNA for protein replacement therapy

Arcturus To Attend 8th Annual SBP Rare Disease Day Symposium: Alagille Syndrome - New Research, New Hope

Arcturus To Attend Biocom Global Life Science Partnering Conference 2017

Arcturus To present at UCSF Rare Disease Symposium: “A New Era of Nucleic Acid Therapeutics to Treat Orphan Diseases”.

BioCentury featuring Arcturus Therapeutics in an article called Getting the Message

Arcturus To Present at BD Boston Conference

Arcturus Therapeutics featured by SCRIP Intelligence publication

Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory

Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression

Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery

Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego

Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego

Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego

Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities

Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego

Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine

Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine

GEN News Featuring Arcturus Therapeutics on its cover page--in Better Targeting, Delivery of RNAi Therapies

Arcturus Therapeutics to Present at 2017 Bio International Convention (Mon June 19th)

Xconomy article on Arcturus Therapeutics, Inc.

GEN article on Arcturus Therapeutics Inc.

Union Tribune article on Arcturus Therapeutics Inc.

The Korea Herald News on Arcturus Therapeutics Inc.

Arcturus Therapeutics Inc. is Listed in the Key Players List; Involved in Non Alcoholic Steatohepatitis Pipeline (NASH)

Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies

Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)

Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic

Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge

Webcast: Arcturus Merger w/Alcobra Conference Call

Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

Arcturus Therapeutics Announces Presentations at Conferences in November

Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st

Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd

Arcturus Therapeutics to Present at NY/NJ CEO Conference on Nov 8th

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7

Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

Arcturus Therapeutics Ltd., to Present at Genetic Rx Conference at Harvard Medical School (Dec 7th), in a Panel Discussion Called “Next Generation RNA Technologies”

Arcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Payne

Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders

Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO

Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference

Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

Arcturus Therapeutics to Present at Three Investor Conferences in September

Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer

Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor

Arcturus Therapeutics Expands Management Team

Arcturus Therapeutics to Present at October Investor Conferences

Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics to Present at Upcoming Investor Conferences

Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics

Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock

Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock

Arcturus to Report Corporate Overview and Financial Results on August 15

Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

Arcturus Therapeutics To Present at Two Investor Conferences in September

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors

Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

Arcturus Therapeutics Expands Platform with STARR™ Technology

Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

Arcturus Therapeutics to Present at Two Investor Conferences in March

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

Arcturus Therapeutics to be Added to Russell 2000® Index

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data